Technology

Xenon Pharmaceuticals

$15.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.54 (-3.27%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell XENE and other stocks, options, and ETFs commission-free!

About XENE

Xenon Pharmaceuticals Inc. Common Shares, also called Xenon Pharmaceuticals, is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada. The listed name for XENE is Xenon Pharmaceuticals Inc. Common Shares.

CEO
Simon Neil Pimstone
Employees
104
Headquarters
Burnaby, British Columbia
Founded
1996
Market Cap
539.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
152.67K
High Today
$16.52
Low Today
$15.55
Open Price
$16.50
Volume
589.12K
52 Week High
$18.45
52 Week Low
$7.00

Collections

XENE Earnings

-$0.49
-$0.33
-$0.16
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 8, After Hours

You May Also Like

VIXM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure